Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
2002 1
2003 1
2004 1
2009 1
2010 1
2011 1
2012 1
2013 2
2015 1
2017 5
2018 9
2019 4
2020 9
2021 9
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD.
Hewitt G, Borel V, Segura-Bayona S, Takaki T, Ruis P, Bellelli R, Lehmann LC, Sommerova L, Vancevska A, Tomas-Loba A, Zhu K, Cooper C, Fugger K, Patel H, Goldstone R, Schneider-Luftman D, Herbert E, Stamp G, Brough R, Pettitt S, Lord CJ, West SC, Ahel I, Ahel D, Chapman JR, Deindl S, Boulton SJ. Hewitt G, et al. Among authors: pettitt s. Mol Cell. 2021 Feb 18;81(4):767-783.e11. doi: 10.1016/j.molcel.2020.12.006. Epub 2020 Dec 16. Mol Cell. 2021. PMID: 33333017 Free PMC article.
The shieldin complex mediates 53BP1-dependent DNA repair.
Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D. Noordermeer SM, et al. Among authors: pettitt sj. Nature. 2018 Aug;560(7716):117-121. doi: 10.1038/s41586-018-0340-7. Epub 2018 Jul 18. Nature. 2018. PMID: 30022168 Free PMC article.
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.
Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, Serrels B, Caligiuri G, Rebus S, Plenker D, Galluzzo Z, Brunton H, Cunningham R, Tesson M, Nourse C, Bailey UM, Jones M, Moran-Jones K, Wright DW, Duthie F, Oien K, Evers L, McKay CJ, McGregor GA, Gulati A, Brough R, Bajrami I, Pettitt S, Dziubinski ML, Candido J, Balkwill F, Barry ST, Grützmann R, Rahib L; Glasgow Precision Oncology Laboratory,; Australian Pancreatic Cancer Genome Initiative, Johns A, Pajic M, Froeling FEM, Beer P, Musgrove EA, Petersen GM, Ashworth A, Frame MC, Crawford HC, Simeone DM, Lord C, Mukhopadhyay D, Pilarsky C, Tuveson DA, Cooke SL, Jamieson NB, Morton JP, Sansom OJ, Bailey PJ, Biankin AV, Chang DK. Dreyer SB, et al. Among authors: pettitt s. Gastroenterology. 2021 Jan;160(1):362-377.e13. doi: 10.1053/j.gastro.2020.09.043. Epub 2020 Oct 9. Gastroenterology. 2021. PMID: 33039466 Free PMC article.
Structural basis for allosteric PARP-1 retention on DNA breaks.
Zandarashvili L, Langelier MF, Velagapudi UK, Hancock MA, Steffen JD, Billur R, Hannan ZM, Wicks AJ, Krastev DB, Pettitt SJ, Lord CJ, Talele TT, Pascal JM, Black BE. Zandarashvili L, et al. Among authors: pettitt sj. Science. 2020 Apr 3;368(6486):eaax6367. doi: 10.1126/science.aax6367. Science. 2020. PMID: 32241924 Free PMC article.
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ. Pettitt SJ, et al. Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2. Nat Commun. 2018. PMID: 29748565 Free PMC article.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S. Chabanon RM, et al. Among authors: pettitt sj. J Clin Invest. 2019 Mar 1;129(3):1211-1228. doi: 10.1172/JCI123319. Epub 2019 Feb 11. J Clin Invest. 2019. PMID: 30589644 Free PMC article.
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Yap TA, et al. Among authors: pettitt sj. J Clin Oncol. 2020 Sep 20;38(27):3195-3204. doi: 10.1200/JCO.19.02404. Epub 2020 Jun 22. J Clin Oncol. 2020. PMID: 32568634 Free PMC article. Clinical Trial.
Modelling the Cancer Phenotype in the Era of CRISPR-Cas9 Gene Editing.
Stewart J, Banerjee S, Pettitt SJ, Lord CJ. Stewart J, et al. Among authors: pettitt sj. Clin Oncol (R Coll Radiol). 2020 Feb;32(2):69-74. doi: 10.1016/j.clon.2019.09.057. Epub 2019 Nov 1. Clin Oncol (R Coll Radiol). 2020. PMID: 31679912 No abstract available.
43 results